Delivery Order SPE2DB24D9802-SPE2DB25FJKWF
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a $12,168.60 firm fixed-price delivery order by the Defense Logistics Agency on September 5, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL. This delivery order, with an ultimate completion date of September 8, 2025, represents a discrete purchase under DMS Pharmaceutical Group's substantial single-award Indefinite Delivery Contract with the DLA valued at...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $5,273.06 by the Defense Logistics Agency (DLA) on August 26, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL. This firm fixed-price delivery order, with an ultimate completion date of August 27, 2025, was issued without a set-aside designation. The contract represents a single delivery order fulfillment under DMS Pharmaceutical...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a delivery order award from the Defense Logistics Agency for HUMIRA (CF) Pen 40 mg/0.4 mls, valued at $5,315.34. The contract was awarded on August 6, 2025, with an ultimate completion date of August 7, 2025, and utilizes firm fixed-price pricing with no set-aside designation. This delivery order represents pharmaceutical supply to support Department of Defense healthcare...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $9,958.88 on August 21, 2025, for HUMIRA (adalimumab) pens containing 40 mg/0.4 mL. The order, with an ultimate completion date of August 22, 2025, was issued by the Defense Logistics Agency under a firm fixed-price contract type with no set-aside designation. Performance of the delivery will take place in Conshohocken, Pennsylvania. This...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $6,489.92 by the Defense Logistics Agency on July 30, 2025, for the supply of HUMIRA (Adalimumab) CF Pen 40 mg/0.4 ml. The contract carries a firm fixed-price structure with no set-aside designation and is scheduled for ultimate completion by July 31, 2025. This delivery order is issued under DMS Pharmaceutical Group's larger single-award...
- This is a $31,320.48 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract covers the supply of the pharmaceutical product HUMIRA(CF) PEN 40 MG/0.4 MLS, with an ultimate completion date of September 21, 2023. DMS Pharmaceutical Group holds a larger $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB...
- The Defense Logistics Agency awarded a delivery order valued at $4,056.20 to DMS Pharmaceutical Group Inc. for HUMIRA (CF) Pen 40 mg/0.4 mL on July 15, 2025, with a completion date of July 16, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was selected under a firm fixed-price contract type with no set-aside designation. The delivery order represents a procurement of the branded immunosuppressant medication used to treat...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $26,437.68 firm fixed-price delivery order is for the supply of HUMIRA(CF) PEN 40 MG/0.4 MLS, a biologic medication. The award is not associated with a set-aside designation. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $3,244.96 to DMS Pharmaceutical Group Inc. for the supply of HUMIRA (adalimumab) CF Pen 40 mg/0.4 mL on April 24, 2025, with an ultimate completion date of April 25, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was selected without a set-aside designation. The delivery order will be performed at the company's location in Park Ridge,...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $59,892.38 contract is for the delivery of HUMIRA(CF) PEN 40 MG/0.4 MLS and does not have a set-aside designation. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for...
- SPE2DB24D9802Indefinite Delivery Contract
- SPE2DB24D9802-SPE2DB25FJKWFDelivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $5,613.94 by the Defense Logistics Agency on April 21, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls. This firm fixed-price delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499.999 billion and valid through November 2026. The contract carries no set-aside designation, allowing the company to compete on the open market while leveraging its woman-owned small business status. Performance is scheduled for completion by April 22, 2025, with delivery to Park Ridge, Illinois. The award reflects DMS Pharmaceutical Group's established role as a critical supplier within the federal pharmaceutical supply chain, providing pharmaceutical products and medications to Department of Defense healthcare facilities nationwide. HUMIRA, a widely prescribed biologic medication used to treat autoimmune conditions, is among the specialty pharmaceutical items included in the company's comprehensive portfolio of branded and generic prescription drugs, biologics, and medical consumables delivered to military and federal healthcare systems. The DLA's use of delivery orders under the SPE2DB IDC enables efficient procurement of essential pharmaceutical supplies to support medical operations across defense healthcare infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.6k | 4/21/25 |